(1) A pharmacist may, in accordance with this section, administer a drug described in Subsection (2).

(2) Notwithstanding the provisions of Subsection 58-17b-102(57)(c)(ii)(B), the division shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, establishing training for a pharmacist to administer the following long-acting injectables intramuscularly: (a) aripiprazole; (b) aripiprazole lauroxil; (c) paliperidone; (d) risperidone; (e) olanzapine; (f) naltrexone; (g) naloxone; and (h) drugs approved and regulated by the United States Food and Drug Administration for the treatment of the Human Immunodeficiency Virus.

(a) aripiprazole;

(b) aripiprazole lauroxil;

(c) paliperidone;

(d) risperidone;

(e) olanzapine;

(f) naltrexone;

(g) naloxone; and

(h) drugs approved and regulated by the United States Food and Drug Administration for the treatment of the Human Immunodeficiency Virus.

(3) A pharmacist may not administer a drug listed under Subsection (2) unless the pharmacist: (a) completes the training described in Subsection (2); (b) administers the drug at a clinic or community pharmacy, as those terms are defined by the division, by administrative rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act; and (c) is directed by the physician, as that term is defined in Section 58-67-102 or Section 58-68-102, who issues the prescription to administer the drug.

(a) completes the training described in Subsection (2);

(b) administers the drug at a clinic or community pharmacy, as those terms are defined by the division, by administrative rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act; and

(c) is directed by the physician, as that term is defined in Section 58-67-102 or Section 58-68-102, who issues the prescription to administer the drug.